drugset / Trial / NCT04019717
Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study will assess the safety and efficacy of AT-527 in combination with daclatasvir after 8 or 12 weeks of treatment.
Timeline
- Start
- 2019-06-20
- Primary completion
- 2020-01-29
- Completion
- 2020-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemnifosbuvir | Other / unclassified | — | — |
| Subject | Daclatasvir | Small molecule | — | — |